Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis
- 1 January 2001
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (10), 1039-1049
- https://doi.org/10.2165/00019053-200119100-00005
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritisClinical Therapeutics, 2001
- Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in SwitzerlandPharmacoEconomics, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Guidelines for the medical management of osteoarthritisArthritis & Rheumatism, 1995
- Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Nabumetone in Elderly Patients with OsteoarthritisPharmacoEconomics, 1994
- The cost‐effectiveness of misoprostol for nonsteroidal antiinflammatory drug–associated adverse gastrointestinal eventsArthritis & Rheumatism, 1993
- Cost-effectiveness of Misoprostol in SwedenInternational Journal of Technology Assessment in Health Care, 1992
- Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugsPublished by Oxford University Press (OUP) ,1990
- Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.BMJ, 1988